行情

ADMA

ADMA

Adma生物制品
NASDAQ

实时行情|Nasdaq Last Sale

4.160
-0.100
-2.35%
盘后: 4.200 +0.04 +0.96% 16:10 01/27 EST
开盘
4.160
昨收
4.260
最高
4.299
最低
4.080
成交量
47.74万
成交额
--
52周最高
6.31
52周最低
2.560
市值
1.89亿
市盈率(TTM)
-3.7246
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADMA 新闻

  • 英国超市巨头承诺投10亿英镑 到2040年实现零排放
  • 新浪财经.1小时前
  • 韩国政府:将全力以赴抗击疫情并稳定金融市场
  • 新浪财经.1小时前
  • 美国父母的儿童早教支出每年高达420亿美元
  • 新浪财经.2小时前
  • 贝佐斯前妻出售亚马逊部分股票套现4亿美元
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

ADMA 简况

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
展开

Webull提供ADMA Biologics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。